PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients

被引：3
|
作者：
Contreras, A.
Herrera, S.
Wang, T.
Mayer, I.
Forero, A.
Nanda, R.
Goetz, M.
Chang, J. C.
Pavlick, A. C.
Fuqua, S. A. W.
Gutierrez, C.
Hilsenbeck, S. G.
Li, M. M.
Osborne, C. K.
Schiff, R.
Rimawi, M. F.
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
[2] Vanderbilt Univ, Nashville, TN 37235 USA
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Univ Chicago, Chicago, IL 60637 USA
[5] Mayo Clin, Rochester, MN USA
[6] Methodist Hosp, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2013年 / 73卷
关键词：
D O I：
10.1158/0008-5472.SABCS13-PD1-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD1-2
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
    Xie, Yifan
    Wu, Siyu
    Zhang, Ying
    Li, Jianwei
    Mo, Miao
    Shao, Zhimin
    Liu, Guangyu
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [22] Neoadjuvant trastuzumab therapy with or without anthracycline containing chemotherapy for HER2-positive primary breast cancer
    Horiguchi, J.
    Koibuchi, Y.
    Rokutanda, N.
    Nagaoka, R.
    Sato, A.
    Odawara, H.
    Tokiniwa, H.
    Kikuchi, M.
    Lino, Y.
    Takeyoshi, I.
    EJC SUPPLEMENTS, 2010, 8 (03): : 73 - 73
  • [23] Impact of PIK3CA mutations and p95HER2 expression on the outcome of HER2-positive metastatic breast cancer patients treated with a trastuzumab-based therapy
    Fontana, Andrea
    Allegrini, Giacomo
    al Zoubi, Mazhar
    Collecchi, Paola
    Mazzanti, Chiara
    Stasi, Irene
    Lucchesi, Sara
    Bona, Eleonora
    Ferrarini, Ilaria
    Salvadori, Barbara
    Arrighi, Giada
    Marcucci, Lorenzo
    Filidei, Mario
    Orlandini, Cinzia
    Falcone, Alfredo
    Bevilacqua, Generoso
    Zavaglia, Katia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] IMPACT OF PIK3CA MUTATIONS AND P95HER2 EXPRESSION ON THE OUTCOME OF HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS TREATED WITH A TRASTUZUMAB-BASED THERAPY
    Stasi, I.
    Fontana, A.
    Allegrini, G.
    Mazzanti, C.
    Lucchesi, S.
    Bona, E.
    Ferrarini, I.
    Salvadori, B.
    Falcone, A.
    Zavaglia, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
  • [25] HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.
    Prat, Aleix
    De Angelis, Carmine
    Pascual, Tomas
    Gutierrez, Carolina
    Llombart-Cussac, Antonio
    Wang, Tao
    Cortes, Javier
    Rexer, Brent Neil
    Veeraraghavan, Jamunarani
    Forero-Torres, Andres
    Wolff, Antonio C.
    Morales, Serafin
    Krop, Ian E.
    Pavlick, Anne Clarisse
    Bermejo, Begona
    Hilsenbeck, Susan G.
    Oliveira, Mafalda
    Schiff, Rachel
    Osborne, C. Kent
    Rimawi, Mothaffar F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] SOLTI-1507: A phase Ib study of ipatasertib and anti-HER2 therapy in HER2-positive advanced breast cancer with PIK3CA mutation (IPATHER)
    Oliveira, M.
    Villagrasa, P.
    Ciruelos, E. M.
    Gavila, J.
    Cortegoso, A.
    Henao, F.
    Vega, E.
    Salvador, J.
    Quiroga, V.
    Estevez, L. G.
    Morales, S.
    Tolosa, P.
    Salvador, F.
    Gonzalez, X.
    Saura, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S389 - S389
  • [27] Solti-1507 A phase ib study of ipatasertib and anti-her2 therapy in her2-positive advanced breast cancer with pik3ca mutation (ipather)
    Oliveira, Mafalda
    Villagrasa, Patricia
    Ciruelos, Eva
    Gavila, Joaquin
    Cortegoso, Alexandra
    Henao, Fernando
    Vega, Estela
    Bofill, Javier S.
    Quiroga, Vanesa
    Garcia-Estevez, Laura
    Morales, Serafin
    Tolosa, Pablo
    Celiz, Pamela
    Farre, Xavier Gonzalez
    Saura, Cristina
    CANCER RESEARCH, 2021, 81 (04)
  • [28] Decreased PTEN expression and PIK3CA mutations in HER-2 positive breast cancer.
    Koninki, K.
    Kauraniemi, P.
    Pitkanen, J.
    Isola, J.
    Tanner, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S211 - S211
  • [29] Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer
    Guarneri, Valentina
    Dieci, Maria Vittoria
    Frassoldati, Antonio
    Maiorana, Antonino
    Ficarra, Guido
    Bettelli, Stefania
    Tagliafico, Enrico
    Bicciato, Silvio
    Generali, Daniele Giulio
    Cagossi, Katia
    Bisagni, Giancarlo
    Sarti, Samanta
    Musolino, Antonino
    Ellis, Catherine
    Crescenzo, Rocco
    Conte, PierFranco
    ONCOLOGIST, 2015, 20 (09): : 1001 - 1010
  • [30] Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial
    Nuciforo, P.
    Prat, A.
    Llombart, A.
    Fasani, R.
    Pare, L.
    Pascual, T.
    Oliveira, M.
    Martinez Janez, N.
    Bermejo De las Heras, B.
    Vidal, M.
    Pernas Simon, S.
    Lopez, R.
    Munoz, M.
    Garau, I.
    Manso, L.
    Alarcon Company, J.
    Martinez de Duenas, E.
    Villagrasa Gonzalez, P.
    Cortes Castan, J.
    Holgado, E.
    ANNALS OF ONCOLOGY, 2017, 28
12345